Alemtuzumab in chronic lymphocytic leukemia treatment: Retrospective analysis of outcome according to cytogenetics;Alemtuzumab v terapii chronické lymfocytární leukemie: Retrospektivní analýze a hodnocení léč ebné odpovědi podle cytogenetického rizika

Vnitrni Lekarstvi

Volumn 55, Issue 6, 2009, Pages 549-554

  Doubek, Michael ^a   Jungova A ^b   Brejcha, M ^c   Panovska A ^a   Brychtova Y ^a   Pospisil Z ^d   Mayer, J ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Hematologicke Oddeleni Onkologickeho Centra J G Mendela Novy Jicin

^d MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Alemtuzumab; Chronic lymphocytic leukemia; Cytogenetic risk; Treatment

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIHISTAMINIC AGENT; CORTICOSTEROID; COTRIMOXAZOLE; FLUDARABINE; PARACETAMOL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INCIDENCE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRISOMY 12;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 67651165078     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Doubek M, Ráčil Z, Mayer J. Klinické využití humanizované monoklonální protilátky alemtuzumab. 1. vyd. Brno: Masarykova univerzita 2006.
2. Dyer MJ. The role of CAMPATH-1H antibodies in the treatment of lymphoid malignancies. Semin Oncol 1999; 26 (5 Suppl 14): S52-S57.
3. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001; 3: 137-143. (Pubitemid 33039652)
4. Lozanski G, Heerema NA, Flinn IW et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278-3281.
5. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347: 452-453. (Pubitemid 34851846)
6. Mayer J, Schwarz J, Doubek M et al. Co nám v kaž dodenní praxi skutečně říkají tzv. moderní prognostické faktory u chronické lymfatické leukemie? Transf Hemat Dnes 2007; 13: 106-116.
7. Hillmen P, Skotnicki AB, Robak T et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616-5623.
8. Keating MJ, Coutré S, Rai K et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004; 4: 220-227. (Pubitemid 38528876)
9. Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916. (Pubitemid 32064784)
10. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
11. Österborg A, Dyer MJS, Bunjes D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567-1574.
12. Lundin J, Kimby E, Björkholm M et al. hase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768-773.
13. Elter T, Borchmann P, Schulz H et al. Development of a new, four-weekly schedule (FluCam) with concomitant aplication of Campath-1H and fludarabine in patients with relapsed/refractory CLL. Proc Am Soc Clin Oncol 2003; 22. Abstract 2331.
14. Montillo M, Tedeschi A, Rossi V et al. Alemtuzumab as consolidation after a response to fludarabine is effective to purge residual disease in patients with chronic lymphocytic leukemia. Blood 2004; 104. Abstract 479.
15. Moreton P, Kennedy B, Rawstron A et al. The correlation between the eradication of minimal residual disease (MRD) following alemtuzumab for CLL and overall survival. Proc Am Soc Clin Oncol 2004; 23. Abstract 6566.
16. Stilgenbauer S, Kröber A, Winkler D et al. Efficacy of subcutaneous alemtuzumab (Campath-1H) in genetic high-risk, fludarabine-refractory CLL: CLL2H study of the German CLL Study Group (GCLLSG). Ann Oncol 2005; 43. Abstrakt 041.
17. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561. (Pubitemid 34534522)
18. Dickinson JD, Gilmore J, Iqbal J et al. 11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules. Leuk Lymphoma 2006; 47: 231-244. (Pubitemid 43084561)
19. Fiegl M, Falkner A, Hopfinger G et al. Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer 2006; 107: 2408-2416.
20. Hui D, Lam W, Toze C et al. Alemtuzumab in clinical practice: a British Columbia experience. Leuk Lymphoma 2008; 49: 218-226. (Pubitemid 351193914)
21. National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available from: http://ctep.cancer.gov/forms/CTCAEv3.pdf.